Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 146 citing articles:

Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure
Lauren B. Arendse, A.H. Jan Danser, Marko Poglitsch, et al.
Pharmacological Reviews (2019) Vol. 71, Iss. 4, pp. 539-570
Open Access | Times Cited: 313
Evaluation of the effect of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR‐Reduced trial
Milton Packer, Javed Butler, Gerasimos Filippatos, et al.
European Journal of Heart Failure (2019) Vol. 21, Iss. 10, pp. 1270-1278
Open Access | Times Cited: 249
Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function
Faı̈ez Zannad, João Pedro Ferreira, Stuart J. Pocock, et al.
Circulation (2020) Vol. 143, Iss. 4, pp. 310-321
Open Access | Times Cited: 217
Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease
Richard Haynes, Parminder K. Judge, Natalie Staplin, et al.
Circulation (2018) Vol. 138, Iss. 15, pp. 1505-1514
Open Access | Times Cited: 189
Renal effects of guideline‐directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology
Wilfried Müllens, Pieter Martens, Jeffrey M. Testani, et al.
European Journal of Heart Failure (2022) Vol. 24, Iss. 4, pp. 603-619
Open Access | Times Cited: 88
Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction
Finnian R. Mc Causland, Brian Claggett, Muthiah Vaduganathan, et al.
JAMA Cardiology (2022) Vol. 8, Iss. 1, pp. 56-56
Open Access | Times Cited: 75
Characterization of the inflammatory‐metabolic phenotype of heart failure with a preserved ejection fraction: a hypothesis to explain influence of sex on the evolution and potential treatment of the disease
Milton Packer, Carolyn S.P. Lam, Lars H. Lund, et al.
European Journal of Heart Failure (2020) Vol. 22, Iss. 9, pp. 1551-1567
Open Access | Times Cited: 127
Sacubitril/Valsartan
Kieran F. Docherty, Muthiah Vaduganathan, Scott D. Solomon, et al.
JACC Heart Failure (2020) Vol. 8, Iss. 10, pp. 800-810
Open Access | Times Cited: 112
Change in renal function associated with drug treatment in heart failure: national guidance
Andrew L. Clark, Paul R. Kalra, Mark C. Petrie, et al.
Heart (2019) Vol. 105, Iss. 12, pp. 904-910
Open Access | Times Cited: 81
Chronic Kidney Disease: Strategies to Retard Progression
Ming-Tso Yan, Chia‐Ter Chao, Shih‐Hua Lin
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 18, pp. 10084-10084
Open Access | Times Cited: 78
Neprilysin Inhibitors in Heart Failure
Biykem Bozkurt, Ajith Nair, Arunima Misra, et al.
JACC Basic to Translational Science (2022) Vol. 8, Iss. 1, pp. 88-105
Open Access | Times Cited: 62
Effect of sacubitril/valsartan on renal function: a systematic review and meta‐analysis of randomized controlled trials
Francesco Spannella, Federico Giulietti, Andrea Filipponi, et al.
ESC Heart Failure (2020) Vol. 7, Iss. 6, pp. 3487-3496
Open Access | Times Cited: 65
Neprilysin inhibition: a new therapeutic option for type 2 diabetes?
Nathalie Esser, Sakeneh Zraika
Diabetologia (2019) Vol. 62, Iss. 7, pp. 1113-1122
Open Access | Times Cited: 57
Do most patients with obesity or type 2 diabetes, and atrial fibrillation, also have undiagnosed heart failure? A critical conceptual framework for understanding mechanisms and improving diagnosis and treatment
Milton Packer
European Journal of Heart Failure (2019) Vol. 22, Iss. 2, pp. 214-227
Open Access | Times Cited: 56
Renal effects of Sacubitril/Valsartan in heart failure with reduced ejection fraction: a real life 1-year follow-up study
Francesco Spannella, Marco Marini, Federico Giulietti, et al.
Internal and Emergency Medicine (2019) Vol. 14, Iss. 8, pp. 1287-1297
Open Access | Times Cited: 55
Chronic kidney disease, heart failure and neprilysin inhibition
Richard Haynes, Doreen Zhu, Parminder K. Judge, et al.
Nephrology Dialysis Transplantation (2019) Vol. 35, Iss. 4, pp. 558-564
Open Access | Times Cited: 54
Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review
Domingo A. Pascual‐Figal, Antoni Bayés‐Genís, Paola Beltrán-Troncoso, et al.
Frontiers in Cardiovascular Medicine (2021) Vol. 8
Open Access | Times Cited: 51
Renal protection in chronic heart failure: focus on sacubitril/valsartan
Roberto Pontremoli, Claudio Borghi, Pasquale Perrone Filardi
European Heart Journal - Cardiovascular Pharmacotherapy (2021) Vol. 7, Iss. 5, pp. 445-452
Open Access | Times Cited: 46
Therapeutic potential of pro-resolving mediators in diabetic kidney disease
Tanwi Vartak, Catherine Godson, Eoin Brennan
Advanced Drug Delivery Reviews (2021) Vol. 178, pp. 113965-113965
Open Access | Times Cited: 42
Kidney Angiotensin in Cardiovascular Disease: Formation and Drug Targeting
Hui Lin, Frank Geurts, Luise Hassler, et al.
Pharmacological Reviews (2022) Vol. 74, Iss. 3, pp. 462-505
Open Access | Times Cited: 32
Why Has it Been Challenging to Modify Kidney Disease Progression in Patients With Heart Failure?
Muthiah Vaduganathan, Brendon L. Neuen, Finnian R. McCausland, et al.
Journal of the American College of Cardiology (2024) Vol. 84, Iss. 22, pp. 2241-2245
Closed Access | Times Cited: 7
The combination of a neprilysin inhibitor (sacubitril) and angiotensin-II receptor blocker (valsartan) attenuates glomerular and tubular injury in the Zucker Obese rat
Javad Habibi, Annayya R. Aroor, Nitin A. Das, et al.
Cardiovascular Diabetology (2019) Vol. 18, Iss. 1
Open Access | Times Cited: 53
Efficacy and safety of sacubitril/valsartan compared with olmesartan in Asian patients with essential hypertension: A randomized, double‐blind, 8‐week study
Yong Huo, Weimin Li, Randy L. Webb, et al.
Journal of Clinical Hypertension (2018) Vol. 21, Iss. 1, pp. 67-76
Open Access | Times Cited: 52
Antioxidant Roles of SGLT2 Inhibitors in the Kidney
Carmen Llorens-Cebrià, Mireia Molina-Van den Bosch, Ander Vergara, et al.
Biomolecules (2022) Vol. 12, Iss. 1, pp. 143-143
Open Access | Times Cited: 27
Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON‐HF
Alexander Peikert, Muthiah Vaduganathan, Finnian R. Mc Causland, et al.
European Journal of Heart Failure (2022) Vol. 24, Iss. 5, pp. 794-803
Open Access | Times Cited: 22
Page 1 - Next Page

Scroll to top